Results 51 to 60 of about 61,500 (274)

VONOPRAZAN IS EFFICACIOUS FOR TREATMENT OF HEARTBURN IN NON-EROSIVE REFLUX DISEASE: A RANDOMIZED TRIAL.

Clinical Gastroenterology and Hepatology
BACKGROUND & AIMS Potassium-competitive acid blockers have documented efficacy for erosive esophagitis. We performed a randomized trial in U.S. subjects diagnosed with non-erosive reflux disease (NERD) of vonoprazan vs.
Loren Laine, Stuart Spechler, Rena H. Yadlapati, F. Schnoll-Sussman, Neil S P Smith, Eckhard Leifke, T. Harris, B. Hunt, Ronnie Fass, Philip Katz   +9 more
semanticscholar   +1 more source

Sustained efficacy following resolution of frequent heartburn with an over-the-counter regimen of esomeprazole 20 mg or placebo for 14 days: two randomized trials

BMC Gastroenterology, 2018
Background A two-week course of therapy with an over-the-counter proton-pump inhibitor (PPI) is recommended for frequent heartburn. Limited research has been conducted on the sustained efficacy of short-term PPI therapy after treatment cessation ...
David A. Peura, Anne Le Moigne, Heather Wassel, Charles Pollack   +3 more
doaj   +1 more source

Diagnosis and outcome of oesophageal Crohn's disease [PDF]

, 2019
BACKGROUND AND AIMS: Crohn's disease (CD) can involve any part of the gastrointestinal tract. We aimed to characterize clinical, endoscopic, histologic features and treatment outcomes of CD patients with oesophageal involvement.
Beaton, D, Chaparro, M, Ellul, P, Katsanos, K, Oliveira, AM, et al., Rodrigues, R, Savarino, E, Sladek, M, Teich, N, van der Woude, J, Vavricka, R, Wei, J   +11 more
core   +1 more source

Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis

Alimentary Pharmacology and Therapeutics, 2019
Proton pump inhibitors (PPIs) are widely used to treat gastro‐oesophageal reflux disease (GORD). However, the onset of action is considered slow and PPIs cannot completely block acid secretion at night.
T. Oshima, Eitatsu Arai, M. Taki, T. Kondo, T. Tomita, H. Fukui, J. Watari, H. Miwa   +7 more
semanticscholar   +1 more source

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction [PDF]

, 2013
Background: This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric ...
Arnold, Dirk, Brenner, Baruch, Galle, Peter R., Gockel, Ines, Klautke, Gunther, Lang, Hauke, Möhler, Markus, Roessler, Hans-Peter, Rödel, Claus, Schimanski, Carl Christoph, Schmidberger, Heinz, Thomaidis, Thomas, Trarbach, Tanja   +12 more
core   +1 more source

Real-World Clinical Utility of a Methylated DNA Biomarker Assay on Samples Collected with a Swallowable Capsule-Balloon for Detection of Barrett’s Esophagus (BE)

Medicina
Background: Barrett’s Esophagus (BE) is the only known precursor for esophageal adenocarcinoma (EAC). Patients with multiple risk factors for BE/EAC are recommended for screening; however, few eligible patients undergo evaluation by endoscopy. EsoGuard® (
Dan Lister, Andy Fine, Shail Maheshwari, Paul S. Bradley, Kimberly Lister, Victoria T. Lee, Brian J. deGuzman, Suman Verma, Lishan Aklog   +8 more
doaj   +1 more source

Clinical and functional features of gastroesophageal refl ux disease in children and adolescents

Patologìâ, 2012
The aim of our work was to study clinical and endoscopic peculiarities, infl uence of H.Pylori infection and gastric acidity on changes of mucosa of the esophagus in children and adolescents with gastroesophageal refl ux disease (GERD). 140 children (93
L.M. Boyarska, K.O. Ivanova, І.B. Skalozubova   +2 more
doaj   +1 more source

Comparison of symptoms, healthcare utilization, and treatment in diagnosed and undiagnosed individuals with diarrhea-predominant irritable bowel syndrome [PDF]

, 2017
OBJECTIVES: Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by symptoms including abdominal pain and altered bowel function. Up to 75% of individuals with IBS may be undiagnosed.
Chang, Lin, Sayuk, Gregory S, Wolf, Ray
core   +2 more sources

Anxiety Associated With Increased Risk for Emergency Department Recidivism in Patients With Low-Risk Chest Pain [PDF]

, 2018
Anxiety contributes to the chest pain symptom complex in 30% to 40% of patients with low-risk chest pain seen in the emergency department (ED). The validated Hospital Anxiety Depression Scale-Anxiety subscale (HADS-A) has been used as an anxiety ...
Fry, Colin, Jimenez, Guadalupe, Kline, Jeffrey A., Koene, Rachael, Musey, Paul I., Jr., Patel, Roma   +5 more
core   +2 more sources

Relative Contributions of Gastrointestinal‐Specific Hypervigilance and Anxiety in Explaining Eating Disorder Symptoms

Journal of Clinical Psychology, EarlyView.
ABSTRACT Objective Gastrointestinal (GI) disturbances and eating disorder symptoms commonly co‐occur. Hypervigilance and anxiety about GI symptoms may motivate eating disorder behaviors to manage and/or avoid GI symptoms. We hypothesized that GI‐specific anxiety would be more strongly associated with dietary restriction and purging than GI‐specific ...
Gabriella Pucci, Naomi G. Hill, Zoe Schneider, Tiffany A. Brown, Helen Burton‐Murray, Livia Guadagnoli, K. Jean Forney   +6 more
wiley   +1 more source